A controlled-release formulation (Wellbutrin XL) was approved in August 2003 as a once-daily formulation for major depression in adults. Zyban received an additional indication for use in combination with nicotine transdermal systems (NTS) for treating the symptoms of smoking cessation in 1999. Another sustained-release oral dosage form, Zyban, was approved for the management of smoking cessation in May 1997. It was reintroduced in July 1989 as an antidepressant (i.e., Wellbutrin), and later in a sustained-release formulation (i.e., Wellbutrin SR). Bupropion hydrochloride was originally approved by the FDA in December 1985 but was removed from marketing for several years due to concern over drug-induced seizures.
Bupropion is also used off-label for multiple neurological/psychological uses, including ADHD and neuropathic pain. The drug has been shown to help people with COPD quit smoking when combined with behavior modification. Bupropion is also indicated for use as an aide to smoking cessation, and is used off-label for addiction to smokeless tobacco. Bupropion has been well tolerated in patients experiencing orthostatic hypotension with tricyclic antidepressant drugs, however, it shows a greater potential for causing seizures than other antidepressants. It is not a tricyclic antidepressant and is unrelated to other known antidepressants. Bupropion is an oral antidepressant drug of the aminoketone class.
0 kommentar(er)
